GlassScriptPhysician profile
Nancy Niparko
NPI 1154442655
$2,405.87
in general payments reported to CMS, 2019-2025
21 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2021: $21.22 · 2022: $219 · 2023: $415 · 2024: $997 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $351.30 | 2023-2024 | Soliris, Ultomiris |
| Grifols USA, LLC | $258.01 | 2022-2023 | Gamunex-C |
| Ucb, INC. | $155.27 | 2023-2024 | Fintepla |
| Biomarin Pharmaceutical INC. | $153.64 | 2024 | Brineura |
| Alnylam Pharmaceuticals INC. | $143.70 | 2025 | Amvuttra |
| Sk Life Science, INC. | $142.11 | 2024-2025 | Xcopri |
| Insightec,INC | $141.34 | 2024 | Exablate |
| Eisai INC. | $125.00 | 2024 | |
| Amgen INC. | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $123.68 | 2024 | Ajovy |
| Allergan, INC. | $118.93 | 2019 | |
| Genzyme Corporation | $111.93 | 2023 | |
| Lilly USA, LLC | $105.40 | 2019 | |
| Acorda Therapeutics, INC | $92.60 | 2022 | |
| Acadia Pharmaceuticals INC | $79.88 | 2023-2024 | Daybue |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $64.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.44 | 2019 | |
| Tolmar, INC. | $31.20 | 2025 | Fensolvi |
| Zealand Pharma US, INC. | $21.22 | 2021 | |
| Mallinckrodt Enterprises LLC | $17.66 | 2019 | |
| Metacel Pharmaceuticals LLC | $4.39 | 2024 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Niparko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.